Abstract:The stable activation of the WNT signaling effector beta-catenin (CTNNB1(ex3)) in ovarian granulosa cells results in the formation of premalignant lesions that develop into granulosa cell tumors (GCTs) spontaneously later in life. Although loss of the tumor suppressor gene Pten alone rarely leads to GCTs, its disruption in granulosa cells that concomitantly express a dominant-stable CTNNB1 mutant accelerates tumor formation. Expression of mutant (oncogenic) KRASG12D in granulosa cells results in the arrest of proliferation, differentiation and apoptosis. In this study, we sought to determine if KRAS activation would retard or block the ovarian phenotype of mice expressing dominant-stable CTNNB1. Unexpectedly, transgenic mice bearing mutations of CTNNB1 and KRAS developed early-onset GCTs leading to premature death in a manner similar to the Ctnnb1;Pten mutant mice. GCT cells in these animals were characterized by increased rates of proliferation, decreased apoptosis and reduced expression of markers of granulosa cell differentiation relative to normal ovaries. Microarray and RT-PCR studies were performed comparing control ovaries, ovaries from mice expressing dominant-stable CTNNB1, and ovaries bearing early-stage tumors from mice with the CTNNB1 mutation and either Pten loss or KRAS activation. Results demonstrated that gene regulatory processes induced by CTNNB1 were mostly further enhanced by either KRAS activation or Pten loss, and that the latter mutations largely affected the expression of the same genes in remarkably similar patterns. Granulosa cells from the tumors proliferate in culture and retain expression of selected CTNNB1 target genes. In addition, concomitant activation of CTNNB1 and KRAS in Sertoli cells resulted in the development of granulosa cell tumors of the testis similar to those observed in the Ctnnb1;Pten mutant mice. Real time-PCR studies showed a partial overlap in gene regulatory processes associated with tumor development in the ovarian and testicular GCTs. Collectively, these results suggest that mutant stable CTNNB1 alters the granulosa cell genetic program and predisposes these cells to transformation whereby either KRAS activation or Pten loss induce GCT development from premalignant lesions via highly similar molecular mechanisms. Supported in part by NIH-HD-16229 and HD-07945 (J.S.R.) and the Canadian Institutes of Health Research (D.B.). (poster)

Rare histologic transformation of a CTNNB1 (β-catenin) mutated prostate cancer with aggressive clinical course

δ-Catenin promotes prostate cancer cell growth and progression by altering cell cycle and survival gene profiles

Androgen signaling is a confounding factor for β-catenin-mediated prostate tumorigenesis

β‐Catenin alterations in testicular Leydig cell tumour: a immunohistochemical and molecular analysis

Wnt/β-catenin Singal Transduction Pathway and Colorectal Cancer

Genotype‐phenotype correlation of CTNNB1 mutations reveals different ß‐catenin activity associated with liver tumor progression

Long noncoding RNA PCAT6 regulates cell growth and metastasis via Wnt/β-catenin pathway and is a prognosis marker in cervical cancer.

β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation

Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma.

Aberrant Wnt/β-Catenin Signaling in Pancreatic Adenocarcinoma

Wnt and β-Catenin Signaling in the Bone Metastasis of Prostate Cancer

Ubiquitin B, Ubiquitin C, and β-Catenin as Promising Diagnostic and Prognostic Tools in Prostate Cancer

Either Kras Activation or Pten Loss Similarly Enhance the Mutant CTNNB1-Induced Genetic Program to Promote Granulosa Cell Tumor Development in Ovary and Testis.

Specific features of ß-catenin-mutated hepatocellular carcinomas

Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene.

WDR1 promotes prostate cancer progression through Wnt/β-catenin signaling

Impact of Aberrant β-Catenin Pathway on Cholangiocarcinoma Heterogeneity

Calcitonin receptor is required for T-antigen-induced prostate carcinogenesis

Wnt/β-catenin signal transduction pathway in prostate cancer and associated drug resistance

Wnt/β-catenin signalling in prostate cancer

Belling the "cat": Wnt/β-catenin signaling and its significance in future cancer therapies